Although the exact mechanism remains largely unclear, there is some evidence to suggest that upregulated ADAM17 in head and neck cancer plays key roles in tumour initiation and progression via proteolytic and/or adhesive properties [20]. Here, ADAM17 is linked to head and neck cancer.